Pharmaceuticals & Drugs - Specialty Formulations and ORS
Strategic Profile
Its flagship product Electral commands a 44% market share, dominating the Oral Rehydration Salt market in India. Key brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm. Over the last 5 years, revenue has grown at a yearly rate of 9.25%, slightly below the industry average of 10.04%.
Cyborg Score Rationale
In 2024, FDC Limited's revenue was ₹21.08 billion, an increase of 8.50% compared to the previous year's ₹19.43 billion, but net profit of FDC declined 23.60% to Rs 28.30 crore in the quarter ended December 2025, indicating profitability headwinds despite revenue growth.
Top Insights
Market-leading Electral brand holds 44% share of India's ORS category with strong consumer loyalty
Recent FDA approvals (Cefixime, Fluconazole) expanding US market opportunity and international footprint
Q3 FY2026 EBITDA margin improved to 11.3% from 10.05% YoY despite top-line pressure
Dividend commitment (Rs 5 per share recently declared) demonstrates shareholder return focus amid transition period
Named Competitors
ORS/Electrolyte Category — Competes with unbranded ORS players and functional beverage manufacturers
Pharmaceutical Formulations — Major competitors in anti-infectives, generics, and specialty formulations
Nutraceuticals — Compete against energy drink and supplement brands in consumer wellness segment
Recent Developments
(February 2026) FDC received USFDA approval for Fluconazole tablets in multiple dosages
(January 2026) Dividend declaration of Rs 5 per share announced
(December 2025) Q3 net profit declined 23.6% YoY to Rs 28.3 crore despite flat revenue
Open the full interactive FDC Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.